Novartis, CH0012005267

Novartis stock draws a Hold consensus before Q3 results

Published on 10/07/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock carries a Hold consensus from 20 analysts, with an average target of USD 145.60 on October 7, 2026. Q3 results are due October 27.

Isometrische Low-Poly-Illustration eines Pharmalabors mit Robotern und Inkubatoren — Novartis AG CH0012005267 – Isometrisches Low-Poly-Labor mit Robotern, Inkubatoren und vielen Wissenschaftlern, Illustration mit AI erstellt.

Novartis stock carries a Hold consensus from 20 analysts, while the shares closed at CHF 117.18 on SIX Swiss Exchange on October 6, 2026. The latest analyst update puts the market focus on valuation and the company's next earnings checkpoint.

Analysts keep a Hold view

According to MarketBeat on October 7, 2026, 20 ratings firms assigned Novartis an average Hold recommendation. The breakdown was 6 Buy ratings, 12 Holds and 2 Sells, with an average 12-month price target of USD 145.60.

Markets Insider reported on October 6, 2026, that Berenberg analyst Kerry Holford maintained a Hold rating and set a CHF 105.00 price target. The target sits below the SIX closing price, keeping the analyst view more cautious than the broader USD consensus.

Q2 growth meets pressure

Novartis reported second-quarter 2026 net sales growth of 3 percent in USD and 1 percent at constant currencies in its July 21, 2026 release. Core operating income was flat in both measures, creating a clear split between sales momentum and profitability.

The company's Q2 sales reached USD 14.4 billion, while core operating income stood at USD 5.9 billion and net income fell 19 percent to USD 3.3 billion, according to ScanX in its October 2026 report. Kisqali sales rose 43 percent at constant currencies to USD 1.7 billion, showing how newer brands are offsetting generic competition.

Q3 date sets the next checkpoint

Novartis reaffirmed its full-year 2026 outlook for low single-digit net sales growth and a low single-digit decline in core operating income at constant currencies in the July 21 release. The next major test arrives on October 27, 2026, when the company has scheduled its Q3 financial results, according to the Novartis investor calendar.

Novartis stock stays below yearly high

Novartis stock closed at CHF 117.18 on SIX on October 6, 2026, with a daily change of +0.60 percent, an intraday high of CHF 118.58 and volume of 2.33 million shares. The 52-week range was CHF 97.05 to CHF 132.68, placing the close CHF 15.50 below the yearly high.